5 › 5.3 › 5.3.3
5.3.3 HF caused by arrhythmia or conduction disease
Pages 29–31 · open in PDF
Recommendations in this section
- Class ILevel CContrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.
- Class ILevel BInitial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.
- Class ILevel CGenetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.
- Class ILevel CInvasive coronary angiography is recommended in patients with HF, angina, and high probability of obstructive CAD who are potential candidates for revascularization.
- Class IIaLevel C18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.
- Class IIaLevel CEndomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.
- Class IIaLevel CRight heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease.
- Class IIbLevel CRight heart catheterization may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state.
- Class IIaLevel CInvasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihood of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.
- Class IIaLevel CCTCA should be considered in patients with HFrEF and low-moderate pre-test likelihood of obstructive CAD.
- Class IIaLevel CReview of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.
- Class IIbLevel CElectrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 29 · PDF
(Figure 8). For frail patients, a typical medical history of angina accompanied by echocardiography showing coronary territory scarring or regional wall motion abnormalities may suffice. In patients with potential for revascularization, further examinations may be needed, considering individual risks and benefits. Computed tomography coronary angiography (CTCA) has a high negative predictive value and should be considered in patients with HF when the likelihood of CAD is low to moderate.196 If patients are possible candidates for revascularization, invasive coronary angiography (ICA) is indicated in patients with HFrEF with a high likelihood of CAD and in patients with angina, regardless of LVEF. Computed tomography coronary angiography and ICA should be used with caution in patients with eGFR <30 mL/ min/1.73 m2 and/or contraindication for contrast medium administration. Evidence supporting the efficacy of viability testing to identify suitable patients for revascularization is lacking.178,179
5.3.2. Investigations for coronary artery disease
5.3.3. Heart failure caused by arrhythmia or conduction disease
Coronary artery disease is highly prevalent in HF and the most common cause of HFrEF.13,33,195 Even though assessment of aetiology is essential in HF, investigations for CAD should be tailored to the individual patient’s risks and benefits
Arrhythmia-associated HF is a broad term that encompasses HF caused by tachyarrhythmias, including AF, atrial flutter, other supraventricular tachycardias, ventricular tachycardia, and premature ventricular contraction (PVC).197,198 The identification
Figure 8 Diagnosis of heart failure due to ischaemic aetiology. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CTCA,
computed tomography coronary angiography; CV, cardiovascular; HF, heart failure; LV, left ventricular. aStress tests include stress echocardiography, stress CMR, or nuclear imaging. Electrocardiographic exercise test has not been shown to properly assess coronary stress.
testing may be needed (see Supplementary data online, Table S2). Advances in multimodal imaging, including CMR, stress testing, and computed tomography (CT), have significantly enhanced our capacity to comprehensively assess HF, offering complementary information that is crucial in complex cases.183–185 CMR is considered the gold standard for assessing LV volumes and mass, owing to its high spatial resolution and reproducibility. Late gadolinium enhancement (LGE) provides detailed insights into fibrosis and scarring and is useful in distinguishing ischaemic from non-ischaemic aetiology as well as certain cardiomyopathies.124 CMR myocardial tissue characterization with parametric mapping [T1, T2, T2* (longitudinal, transverse, and observed transverse relaxation times), LGE and extracellular volume (ECV) expansion] enables classification of cardiomyopathies124,186–193 and of cardiac amyloid.194 An overview of typical CMR findings in cardiomyopathies can be found in the 2023 ESC Guidelines for the management of cardiomyopathies.124 Description of other specific imaging modalities is provided in the Sections on specific comorbidities.
Page 30 · PDF
The diagnosis is a diagnosis of elimination, and it may only be reached retrospectively, if LV function improves following cardiac resynchronization therapy (CRT) implantation.204 In terms of likelihood of response, there is a spectrum. At one end, abnormal cardiac conduction may be the sole culprit, whereas at the other, it may be a bystander in the context of HF due to other causes (Figure 9). CMR may be useful in identifying myocardial scar and morphological abnormalities pointing to other aetiologies of HF. Abnormal cardiac conduction, as the sole cause of HFrEF, is most likely in patients with HFrEF, LBBB, wide QRS duration, with no myocardial scarring on CMR and in patients with RV pacing-induced HF.199
Recommendation Table 4 — Recommendations for specialized diagnostic investigations in patients with established heart failure to detect reversible/treatable causes of heart failure (see Evidence Tables 20–28) Classa
Invasive coronary angiography is recommended in patients with HF, angina, and high probabilityc of obstructive CAD who are potential candidates for revascularizationd.
18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.181,182
Recommendations Investigations for underlying aetiology in patients with HFpEF or HFrEF Contrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.205–215 Initial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.216–222 Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.223–227
Endomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.228 Right heart catheterizatione should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease.229 Right heart catheterizationf may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state.230,231 Invasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihoodc of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.178–180 CTCA should be considered in patients with HFrEF and low-moderate pre-test likelihoodc of obstructive CAD.196,232–234 Review of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.202,235–239 Electrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.240
18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; AF, atrial fibrillation; CAD, coronary artery disease; CIED, cardiac implantable electronic device; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; RV, right ventricular. a Class of recommendation. b Level of evidence. c Based on cardiovascular risk factors and clinical history. d Exclude frailty, multiple severe comorbidities, limited life expectancy. e Right and left heart catheterization needed for the differential diagnosis of constrictive pericarditis and restrictive cardiomyopathy. f Potentially including exercise right heart catheterization.
Investigations for patients with HFrEF
of arrhythmia-associated HF is important in patients with HFrEF, in whom a rhythm strategy for AF may potentially be beneficial. The diagnostic work-up may include an ECG and ambulatory ECG to characterize the electrical subtype, and CMR imaging to characterize the morphological/functional subtype. Arrhythmias may be the sole cause of HFrEF or merely a bystander in the context of other causes of HF. Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to abnormal electrical conduction and should be suspected in patients with LV dysfunction and a QRS duration ≥130 ms, without evidence of other causes for HF.199 It should also be considered in patients with implanted pacemakers or implantable cardioverter-defibrillators (ICDs) delivering RV pacing (see Section 6.2.2.2).200–203
Page 31 · PDF
cardiac implantable electronic device; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle branch block; PET, positron emission tomography; PMT, pacemaker tachycardia; PVC, premature ventricular contraction; RBBB, right bundle branch block; RV, right ventricular; SVT, supraventricular tachycardia; VT, ventricular tachycardia; WHF, worsening heart failure.
6. Management of chronic heart failure
Importantly, AMT and GDIT based on the underlying cause of HF, phenotypical characteristics, and comorbidities are discussed in other sections.
6.1. Guideline-directed medical therapy for heart failure
6.1.1. Goals of pharmacotherapy for patients with heart failure
The Task Force have decided to introduce the terms FMT and AMT, as described in Section 3 (Figure 3). Together FMT and AMT cover GDMT. For HFrEF, FMT currently includes beta-blockers, ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is, whereas for HFpEF it includes SGLT2-Is and MRAs.
Pharmacotherapy remains the cornerstone of treatment for stage C HF and should be implemented at doses used in RCTs in patients with HF before considering device therapy, and alongside non-pharmacological interventions (Figure 1 and Table 11). There are three major goals of treatment for patients with HF: (i) reduction in mortality; (ii) prevention of recurrent
Figure 9 Diagnosing arrhythmia-associated heart failure and heart failure with abnormal cardiac conduction. AF, atrial fibrillation; CIED,